<- Go Home
CardioDx, Inc.
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not a non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California with an additional office in Palo Alto, California.
Market Cap
N/A
Volume
N/A
Cash and Equivalents
3.9M
EBITDA
-35.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
646.0K
Profit Margin
8.11%
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-37.0M
Return on Equity
77.37%
Return on Assets
-42.78
Cash and Short Term Investments
26.6M
Debt
N/A
Equity
30.0M
Revenue
8.0M
Unlevered FCF
-20.8M
Sector
Health Care Equipment and Supplies
Category
N/A